306 related articles for article (PubMed ID: 20837940)
1. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
[TBL] [Abstract][Full Text] [Related]
2. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
[TBL] [Abstract][Full Text] [Related]
3. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
Hess G; Smith SM; Berkenblit A; Coiffier B
Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
5. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
8. Temsirolimus for the treatment of mantle cell lymphoma.
Hess G
Expert Rev Hematol; 2009 Dec; 2(6):631-40. PubMed ID: 21082954
[TBL] [Abstract][Full Text] [Related]
9. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
[TBL] [Abstract][Full Text] [Related]
10. [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Forstpointner R; Hänel A; Repp R; Hermann S; Metzner B; Pott C; Hartmann F; Rothmann F; Böck HP; Wandt H; Unterhalt M; Hiddemann W
Dtsch Med Wochenschr; 2002 Oct; 127(43):2253-8. PubMed ID: 12397539
[TBL] [Abstract][Full Text] [Related]
11. Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies.
Coiffier B; Ribrag V
Leuk Lymphoma; 2009 Dec; 50(12):1916-30. PubMed ID: 19757306
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma.
Witzig TE; Reeder CB; LaPlant BR; Gupta M; Johnston PB; Micallef IN; Porrata LF; Ansell SM; Colgan JP; Jacobsen ED; Ghobrial IM; Habermann TM
Leukemia; 2011 Feb; 25(2):341-7. PubMed ID: 21135857
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Bartlett NL; Johnson JL; Wagner-Johnston N; Ratain MJ; Peterson BA;
Cancer Chemother Pharmacol; 2009 Apr; 63(5):793-8. PubMed ID: 18648813
[TBL] [Abstract][Full Text] [Related]
14. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
15. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.
Witzig TE; Vose JM; Zinzani PL; Reeder CB; Buckstein R; Polikoff JA; Bouabdallah R; Haioun C; Tilly H; Guo P; Pietronigro D; Ervin-Haynes AL; Czuczman MS
Ann Oncol; 2011 Jul; 22(7):1622-1627. PubMed ID: 21228334
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Zinzani PL; Magagnoli M; Moretti L; De Renzo A; Battista R; Zaccaria A; Guardigni L; Mazza P; Marra R; Ronconi F; Lauta VM; Bendandi M; Gherlinzoni F; Gentilini P; Ciccone F; Cellini C; Stefoni V; Ricciuti F; Gobbi M; Tura S
J Clin Oncol; 2000 Feb; 18(4):773-9. PubMed ID: 10673518
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
[TBL] [Abstract][Full Text] [Related]
18. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
19. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma.
Barnes JA; Jacobsen E; Feng Y; Freedman A; Hochberg EP; LaCasce AS; Armand P; Joyce R; Sohani AR; Rodig SJ; Neuberg D; Fisher DC; Abramson JS
Haematologica; 2013 Apr; 98(4):615-9. PubMed ID: 23144193
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network study.
Fenske TS; Shah NM; Kim KM; Saha S; Zhang C; Baim AE; Farnen JP; Onitilo AA; Blank JH; Ahuja H; Wassenaar T; Qamar R; Mansky P; Traynor AM; Mattison RJ; Kahl BS
Cancer; 2015 Oct; 121(19):3465-71. PubMed ID: 26079295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
